JPMorgan Downgrades Allogene Therapeutics Amid Safety Concerns
JPMorgan cuts Allogene Therapeutics rating to Underweight after company removes CD52 component from cema-cel treatment following fatal event. Near-term outlook remains "challenging."
Already have an account? Sign in.